Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide

Markets Investing.com By Investing.com 06 Jun 2026 19:15 1 min read

Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide

Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide

Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide

Read the full story on Investing.com → Opens the original article on www.investing.com

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.